Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

R. Borovik, R. Epelbaum, Y. Cohen, E. Robinson

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.

Original languageEnglish
Pages (from-to)517-518
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number4
StatePublished - 1 Jan 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer'. Together they form a unique fingerprint.

Cite this